$100.00
In stock
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 | — | $100.00 |
| 3 | 30 % | $70.00 |
| 6 | 35 % | $65.00 |
| 12+ | 40 % | $60.00 |
Free bacteriostatic water with every order.
Research suggests the CJC-1295 and Ipamorelin peptide combination may support growth hormone release in controlled laboratory studies. This effect is linked to activation of the anterior pituitary gland.
These peptides are believed to act on complementary pathways that regulate endogenous growth hormone secretion. Because of this, they are widely studied in hormonal signaling, recovery, and physiological support.
This peptide blend has gained attention in experimental research focused on growth hormone pathways and metabolic function.
Use our Research Peptide Storage Guide — Laboratory Use Only — to ensure proper handling and stability for controlled experimental applications. Not for human consumption, therapeutic, or diagnostic use.
Chemical Formula: Sequence-dependent (two peptide analogs combined)
Molecular Weight: ~6,000–8,000 g/mol (sum of individual peptide masses)
CAS Number: Designated upon structural registration
Structure: A co-administration or co-formulation of the long-acting GHRH analog CJC-1295 (with DAC) and the ghrelin receptor agonist Ipamorelin to synergistically stimulate growth hormone release
Form: Lyophilized peptide powder (single vial or combined dosing)
Solubility: Soluble in sterile water or compatible buffer solutions
Stability: Stable when frozen; limited stability after reconstitution
Half-Life:
CJC-1295 with DAC: Extended half-life (days)
Ipamorelin: Shorter half-life (minutes to ~1 hour)
Storage: Store refrigerated at 36–46°F (2–8°C); protect from light and moisture
CJC-1295 activates GHRH receptors while Ipamorelin stimulates growth hormone secretagogue receptors to enhance pulsatile GH release
CJC-1295 with DAC extends duration of action, while Ipamorelin enhances controlled secretion dynamics
Supports downstream insulin-like growth factor-1 production through natural GH signaling
Promotes protein synthesis, fat metabolism, and tissue repair via endogenous hormone pathways
Studied for significantly increased GH secretion compared to single-agent administration
Investigated for improved lean mass support and reduction in visceral adiposity markers
Explored for enhanced regenerative signaling in musculoskeletal and connective tissue models
Evaluated for improved lipid utilization, energy regulation, and metabolic adaptation
Studies demonstrate:
Increased amplitude and frequency of GH pulses
Sustained IGF-1 elevation with combined administration
Improved GH secretory patterns relative to monotherapy
Research indicates:
Increased lean mass markers in experimental models
Reduced adipose tissue relative to baseline
Improved lean-to-fat ratio over extended protocols
Evidence suggests:
Enhanced protein synthesis signaling
Improved connective tissue repair markers
Positive effects on muscle recovery and anabolic tone
Studies show:
Synergistic GH release without significant suppression of natural pulsatility
Prolonged hormonal response due to DAC extension plus secretagogue activation
Favorable endocrine profile in controlled research settings
Temporary fluid retention, joint stiffness, mild injection site irritation
Temporary abdominal bloating, mild gastrointestinal discomfort
Transient increases in blood glucose in sensitive individuals
IGF-1 levels, fasting glucose, blood pressure, fluid retention markers
CJC-1295 + Ipamorelin is intended for research purposes and is typically administered under controlled study protocols.
Independent laboratory testing confirms purity and composition
Purity
Batch
Date
